These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 11720324)
21. Use of infliximab in the treatment of Crohn's disease in children and adolescents. Hyams JS J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S36-9. PubMed ID: 11685974 [No Abstract] [Full Text] [Related]
22. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile]. Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277 [TBL] [Abstract][Full Text] [Related]
23. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. del Valle García-Sánchez M; Gómez-Camacho F; Poyato-González A; Iglesias-Flores EM; de Dios-Vega JF; Sancho-Zapatero R Inflamm Bowel Dis; 2004 Sep; 10(5):701-2. PubMed ID: 15472541 [No Abstract] [Full Text] [Related]
24. Systemic amyloidosis with Crohn's disease treated with infliximab. Park YK; Han DS; Eun CS Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971 [No Abstract] [Full Text] [Related]
25. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Katsanos KH; Christodoulou DK; Zioga A; Tsianos EV Inflamm Bowel Dis; 2003 Jul; 9(4):279. PubMed ID: 12902853 [No Abstract] [Full Text] [Related]
30. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Ryan BM; Romberg M; Wolters F; Stockbrugger RW Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):941-2. PubMed ID: 15316423 [TBL] [Abstract][Full Text] [Related]
31. Prolonged duration of response to infliximab in early pediatric Crohn's disease. Kugathasan S J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S40-3. PubMed ID: 11685975 [No Abstract] [Full Text] [Related]
32. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent? Cuffari C; Lichtenstein GR Gastroenterology; 2003 Jun; 124(7):1988-90. PubMed ID: 12806638 [No Abstract] [Full Text] [Related]
33. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease. Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868 [TBL] [Abstract][Full Text] [Related]
34. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Manni E; Barachini P Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070 [TBL] [Abstract][Full Text] [Related]
36. Tuberculosis and treatment with infliximab. Zhang Z; Correa H; Bégué RE N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859880 [No Abstract] [Full Text] [Related]
37. Infliximab (Remicade), a new biological treatment for Crohn's disease. D'Haens GR Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573 [TBL] [Abstract][Full Text] [Related]
38. TNF-alpha antagonists for the treatment of Crohn's disease. Kam LY; Targan SR Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506 [TBL] [Abstract][Full Text] [Related]
39. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Keating GM; Perry CM BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485 [TBL] [Abstract][Full Text] [Related]
40. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]